Adagio Medical Secures U.S. Food and Drug Administration IDE Approval to Study Its Next-Generation vCLAS® Ventricular Ablation System
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio”), a medical technology company focused on advancing catheter-based ablation solutions for cardiac arrhythmias, has announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval to expand its ongoing FULCRUM-VT clinical trial. The expansion will enable the company to evaluate the safety and effectiveness of its next-generation vCLAS Ultra-Low Temperature Ablation (ULTA) Ventricular Ablation System for the treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT), a serious and potentially life-threatening heart rhythm disorder.
The IDE expansion represents a key regulatory and clinical milestone for Adagio Medical as it continues to build upon its proprietary ULTA platform, which is designed to deliver ultra-low temperature energy for cardiac ablation procedures. Ventricular tachycardia (VT), particularly sustained monomorphic ventricular tachycardia, remains one of the most challenging arrhythmias to treat due to the complexity of underlying cardiac substrates and the difficulty of achieving sufficiently deep and durable lesions with existing ablation technologies.
Dr. William Stevenson, M.D., Professor of Medicine and Principal Site Investigator at Vanderbilt University Medical Center, emphasized the clinical challenges associated with VT treatment and the potential advantages of Adagio’s ULTA technology. He noted that conventional ablation approaches are often limited in their ability to create lesions that penetrate deeply enough into the myocardial tissue, which can result in incomplete treatment and recurrence of arrhythmias. According to Dr. Stevenson, early clinical experience with the initial ULTA system has demonstrated promising safety and efficacy outcomes in patients with both ischemic and non-ischemic cardiomyopathies. He also highlighted expectations that the next-generation system will offer improved catheter maneuverability and reduced freeze times, potentially leading to shorter and more efficient procedures.
The newly approved IDE expansion allows Adagio to initiate a clinical sub-study within the broader FULCRUM-VT trial. This sub-study will specifically evaluate the company’s next-generation vCLAS Ventricular Ablation System, including the advanced vCLAS Ultra catheter. The design of this catheter builds upon the clinical foundation established by Adagio’s earlier all-endocardial ULTA technology, which has been developed to deliver precise and effective ablation through a minimally invasive approach.
One of the defining features of the vCLAS Ultra catheter is its ability to achieve extremely low ablation temperatures, reaching approximately -170°C. This ultra-low temperature capability enables highly efficient single-freeze applications, which have been shown in preclinical studies to produce effective and durable lesions while significantly reducing procedure time. In some models, the technology has demonstrated greater than a 50% reduction in ablation time compared to conventional approaches, suggesting the potential for improved workflow efficiency in clinical practice.
Alex Babkin, Chief Technology Officer of Adagio Medical, highlighted the technological advancements incorporated into the vCLAS Ultra system. He explained that the catheter was designed to enhance multiple aspects of the ablation procedure, including energy delivery, navigation, lesion formation, and overall workflow efficiency. Babkin noted that the development of the system reflects the company’s ability to rapidly integrate feedback from physician partners into meaningful design improvements. In addition to clinical performance enhancements, the next-generation system also incorporates manufacturing optimizations aimed at improving scalability and reducing overall system costs.
Babkin further emphasized that the vCLAS Ultra catheter has the potential to serve as a versatile, single-device solution capable of treating a wide range of ventricular tachycardia substrates through a fully endocardial approach. This capability could simplify procedural workflows and expand access to advanced ablation therapies across a broader range of electrophysiology practices. The IDE approval for the study expansion is therefore viewed as a critical step toward validating what the company believes could represent a transformative advancement in VT treatment.
The sub-study associated with the IDE expansion is designed as a prospective, single-arm, multi-center, pre-market clinical supplemental study. Its primary objective is to generate safety and efficacy data for the use of the next-generation vCLAS Ventricular Ablation System in patients with scar-mediated SMVT. This patient population includes individuals with both ischemic and non-ischemic cardiomyopathies, consistent with the population enrolled in the pivotal phase of the FULCRUM-VT trial.
The study will enroll a total of 55 patients in a staged design, allowing for careful evaluation of clinical outcomes as the trial progresses. Data generated from this sub-study will contribute to the overall evidence base supporting the ULTA platform and may play an important role in future regulatory submissions and commercialization efforts.
Todd Usen, Chief Executive Officer of Adagio Medical, underscored the significance of the IDE expansion in the context of the company’s broader clinical and strategic objectives. He noted that the ULTA technology has already demonstrated the ability to create deep and effective lesions through a fully endocardial approach, supported by a growing body of clinical evidence. The next-generation vCLAS Ultra catheter builds on this foundation with the goal of enabling broader adoption across electrophysiology practices.
Usen also highlighted the company’s long-term vision of developing a scalable solution that can expand access to VT treatment for a large and underserved patient population. Ventricular tachycardia affects a significant number of patients worldwide, many of whom have limited treatment options due to the complexity of their condition. By improving procedural efficiency, reducing treatment times, and enhancing clinical outcomes, Adagio aims to position its technology as a preferred option for clinicians managing these challenging cases.
In addition, Usen expressed appreciation for the collaborative role of the FDA in advancing the development of innovative medical technologies. He noted that the IDE approval reflects ongoing engagement between the company and regulatory authorities, supporting the timely progression of clinical studies while maintaining rigorous safety and efficacy standards.
Overall, the expansion of the FULCRUM-VT trial marks an important advancement for Adagio Medical as it continues to refine and validate its ULTA platform. By combining cutting-edge engineering with clinical insights, the company is working to address longstanding challenges in the treatment of ventricular tachycardia. The results of the upcoming sub-study will be closely watched as they have the potential to shape the future of catheter ablation technologies and improve outcomes for patients with complex cardiac arrhythmias.
About Adagio Medical Holdings, Inc.
Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA, formerly known as ULTC) technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue in an endocardial only approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.
Source Link:https://www.businesswire.com/
